CD4-CCR5工程类重组二价抗体的慢病毒包装及制备  

Lentivirus Packaging and Preparation of CD4-CCR5 Recombinant Antibody

作　　者：易俊波[1] 毛新[1] 买制刚[1] 李凌云[1] 周兆平[1] 苏庆宁[1] 

机构地区：[1]深圳大学生化工程技术研究中心,中国广东深圳518057

出　　处：《生命科学研究》2017年第1期10-15,共6页Life Science Research

基　　金：深圳市自主创新生物产品研发资助计划项目(003646)

摘　　要：人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染与白细胞分化抗原分子CD4和趋化因子受体分子CCR5有着紧密的联系。为了研制可与HIV病毒特异性结合,并能有效预防和治疗HIV感染的抗HIV基因工程二价类重组药物,将人抗体重链恒定区IgG与CD4相连接,CCR5与人抗体轻链恒定区连接,分别构建慢病毒质粒,共转染并筛选,得到高效稳定表达的细胞株。重组抗体经分子生物学及细胞免疫学检测,证实具有抗HIV病毒感染的功能,有一定的经济价值。The human immunodeficiency virus （HIV） has a close connection with CD4 and CCR5 molecules. In order to develop a recombinant drug which can specifically bind to the HIV and can effectively prevent and treat HIV infection, the heavy chain constant region of human IgG was connected with CD4 and the light chain constant region of human IgG was connected with CCR5. The cell lines stably expressing both chains were screened following constructed lentivirus co-infection. The recombinant antibody was proved to have anti-HIV function by molecular biology and cellular immunology tests, and may have clinical values in HIV studies.

关 键 词：人类免疫缺陷病毒(HIV) CD4 CCR5 重组抗体 慢病毒 蛋白质表达 

分 类 号：Q511[生物学—生物化学]